This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Insulin detemir

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • differs from human insulin in that it has the terminal amino acid (B30) in the B-chain deleted, and a 14-carbon fatty acid attached at position B29
    • has a prolonged duration of action (up to 24 hours) mediated by two mechanisms:
      • mainly via , albumin binding via the fatty acid side-chain, which retains insulin in the subcutaneous depot
      • strong self-association of insulin detemir hexamers at the injection site
      • licensed for the treatment of diabetes, to be administered subcutaneously once or twice daily depending on patients' needs, in combination with meal-related short- or rapid-acting insulin
      • efficacy and safety of insulin detemir have not been studied in children and adolescents, nor is there any clinical trial experience in pregnancy
    • a review concluded that (1):
      • both insulin detemir and insulin glargine seem to result in glycaemic control that is at least comparable to that with isophane insulin
      • insulin detemir appears to reduce nocturnal hypoglycaemia and result in less weight gain than does isophane insulin in patients with type 1 diabetes

Reference:

  1. Drug and Therapeutics Bulletin (2004); 42(10):77-80.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.